This study is in progress, not accepting new patients
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
a study on Transitional Cell Carcinoma
Urothelial Cancer P-D1 PD-1 PD1 P-DL1 PD-L1 PDL-1 PDL1 Bladder cancer Pembrolizumab
Lead Scientist at UCSF
- Lawrence Fong
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Merck Sharp & Dohme Corp.
- Phase 2
- Study Type
- Last Updated